Okuda Toshimitsu, Yoshida Norimasa, Takagi Tomohisa, Handa Osamu, Kokura Satoshi, Ichikawa Hiroshi, Naito Yuji, Yoshikawa Toshikazu
Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Dig Dis Sci. 2008 Mar;53(3):657-63. doi: 10.1007/s10620-007-9931-0. Epub 2007 Sep 1.
The aim of the present study was to examine the effect of angiotensin II type I receptor antagonist, CV-11974, on indomethacin-induced small intestinal injury in rats. Single administration of indomethacin provoked severe inflammatory lesions in the small intestine. The levels of thiobarbituric acid-reactive substances (TBARS), myeloperoxidase (MPO) activities and cytokine-induced neutrophil chemoattractant-1 (CINC-1) in the intestinal mucosa significantly increased in the indomethacin-treated group compared with the sham group. In addition, the angiotensin II type I receptor was increased in the small intestine after the administration of indomethacin. The development of intestinal lesions in response to indomethacin was prevented by pretreatment with CV-11974 together with significant suppression of the increased level of TBARS, MPO activities and CINC-1. These results indicate that CV-11974 protected against the small intestinal damage elicited by indomethacin, which suggests that angiotensin II/AT1 receptor interaction is involved in the pathogenesis of the intestinal inflammation associated with oxidative stress.
本研究的目的是检测血管紧张素II 1型受体拮抗剂CV-11974对吲哚美辛诱导的大鼠小肠损伤的影响。单次给予吲哚美辛可引发小肠严重的炎症性病变。与假手术组相比,吲哚美辛治疗组肠黏膜中硫代巴比妥酸反应性物质(TBARS)水平、髓过氧化物酶(MPO)活性及细胞因子诱导的中性粒细胞趋化因子-1(CINC-1)显著升高。此外,给予吲哚美辛后小肠中血管紧张素II 1型受体增加。CV-11974预处理可预防吲哚美辛诱导的肠道病变,并显著抑制TBARS水平升高、MPO活性及CINC-1。这些结果表明,CV-11974可保护免受吲哚美辛引起的小肠损伤,这表明血管紧张素II/AT1受体相互作用参与了与氧化应激相关的肠道炎症的发病机制。